TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria::~* age 18 - 65 inclusive~* able to read and understand informed consent~* informed consent given~* currently being treated with an SSRI for depression or dysthymia~* currently suffering from treatment-emergent sexual dysfunction attributable to the SSRI~* have normal safety lab values at screen~* if currently taking medication to improve sexual performance, willing to discontinue the drug for the duration of the study~* female subjects of child bearing age need to use an acceptable form of birth control throughout the study Exclusion Criteria:- being pregnant, breastfeeding, or planning to become pregnant within 4 months~* suffering from psychotic, substance abuse, bipolar, or organic mental disorder, OCD, panic disorder, or personality disorder severe enough to interfere with study participation~* suffer from an unstable or serious medical disorder~* having a medical disorder that could be the cause of the sexual dysfunction~* taking a medication that is metabolized by hepatic enzyme CYP2D6~* having used a MAOI within 15 days of proposed start of duloxetine treatment~* having a known hypersensitivity to duloxetine or any of its ingredients~* having taken viagra or related drug within 3 months prior to starting SSRI treatment~* requiring ongoing treatment with a mood stabilizer (anticonvulsant) or antipsychotic medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of clear cell renal cell carcinoma~  * Metastatic disease~* Measurable disease~* Previously treated with high-dose aldesleukin OR not eligible for or refused such therapy~* No brain metastases by MRI or CT scan~* HLA-partially matched (e.g., ≥ 2/6 HLA A, B, Dr match) related donor available~  * Patients who have no partially matched immediate family member available are eligible if they have a fully HLA-matched donor~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Bilirubin ≤ 2 times upper limit of normal~* Creatinine clearance ≥ 40 mL/min~* AST ≤ 3 times ULN~* Cardiac ejection fraction ≥ 45%~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Irradiated allogeneic lymphocytes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Have previously participated in a Gilead-sponsored chronic hepatitis C study as an adolescent or pediatric participant and received at least one Gilead HCV direct acting antiviral~* Parent or legal guardian able to provide written informed consent OR individual is able to provide written informed consent prior to any study procedures and willing to comply with study requirements as determined by institutional review board (IRB)/independent ethics committee(IEC)/local requirements and Investigator's discretion.~* Individual is able to provide written assent, if they have the ability to read and write, as determined by IRB/IEC/local requirements and Investigator's discretion~Key Exclusion Criteria:~* Individual is currently receiving or plans to initiate a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up Registry.~* History of clinically-significant illness or any other major medical disorder that may interfere with the individual's follow-up, assessments or compliance with the protocol.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effective Conversion of Individuals at Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High risk of OSA and/or AFib, as defined by the risk algorithm developed by Sanford health~* 18 years or older, with sufficient English language skills~* Owning a smartphone with a relatively new operating system (iOS v. 14 (Iphone 6S or higher) or an Android device v.11\<)~* Able to download and handle an app on a smartphone~* Willing and able to give informed consent~Exclusion criteria:~* Diagnosed with OSA and/or AFib~* Diagnosed health issues that are potentially life threatening or causing mental issues (stroke, Alzheimer's Disease, depression, etc.)~* Pregnancy/breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Smartphone app use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Sucrose to Relieve Pain During Eye Exams in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All premature infants admitted to the Neonatal Intensive Care Unit requiring serial dilated examinations to assess for retinopathy of prematurity will be candidates for this study. This includes all infants with a birthweight of less than 1500 g and infants between 1500 g and 2000 g who require supplemental oxygen.~Exclusion Criteria:~* Any infant who is unable to safely suckle 0.5 cc of fluid will be excluded from the study. This includes infants that are being maintained on ventilators and those with serious gastrointestinal complications that may be exacerbated by an oral fluid bolus.~* Any infant being maintained on narcotics for any reason will not be eligible for the study.~* All infants with major congenital anomalies will be excluded.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hypothermia After In-hospital Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* in-hospital cardiac arrest~* restoration of spontanous circulation~* unconsciousness~* age over 18~* initiation of mild therapeutic hypothermia is possible within 4h after resuscitation~Exclusion Criteria:~* active bleeding~* suspicion of intra cranial bleeding~* severe infection~* aquired immun deficency~* severe rhythm disorders~* suspicion of cerebral insult~* known severe cognotive deficit before the index event~* pregnancy~* pre existing disease which makes 6 months survival unlikely

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard therapy as used in the hospital's ICU
- Hypothermia (Type: ACTIVE_COMPARATOR): Standard therapy as used in the hospital's ICU plus Hypothermia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Glycine Supplement for Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any age.~* Any sex.~* With COVID-19 confirmed (or awaiting confirmation) by PCR.~* With a clinical decision of initiation of mechanical ventilation or with \<48 h under mechanical ventilation.~* Informed consent signed by the participant's responsible.~Exclusion Criteria:~* Pregnant women.~* Already participating in another research protocol.~Elimination Criteria:~* Voluntary hospital discharge or referenced to another institution.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glycine (Type: EXPERIMENTAL): Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
- Control (Type: NO_INTERVENTION): Participants will receive the habitual treatment for their severe condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve for their stage IIIC/IV AJCC 8 non-small cell lung cancer with a tumor biopsy PD-L1 TPS \> 50%~* Intent to treat with PD-1/PD-L1 or PD-1/PD-L1 plus pemetrexed/carboplatin or paclitaxel/nab-paclitaxel/carboplatin~* ECOG PS 0-2~* Ability to consent to participate in the study~Exclusion Criteria:~* Ability to understand the requirements of the protocol or to provide informed consent is impaired or is unwilling to comply with the protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PD1/PD-L1 (Type: None): Standard of Care: PD1/PD-L1 monotherapy
- PD1/PD-L1 + chemo (Type: None): Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Embolization of Pelvic Varicosities in Patients With Pelvic Congestion Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pelvic pain (lasting for more than 6 months)~* Symptoms of PCS - deterioration of pain when standing and improvement in supine position (with or without dyspareunia or dysmenorrhea).~* Confirmed pelvic varicosities by magnetic resonance examination.~* Signed, written and informed consent~Exclusion Criteria:~* Inability to communicate in Norwegian~* Known endometriosis~* Uterine myoma, uterine anomalies, or cancer~* Postmenopausal~* not having been pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pelvic vein embolization (Type: EXPERIMENTAL): female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation~2. Men and women aged ≥ 25 - 80 (included) years of age~3. Hospitalized patients with two absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following HOSPITALIZATION:~4. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated / ventilated for respiratory failure~5. Confirmed infection with COVID-19 by any acceptable test available / utilized at each site~6. Willingness and ability to practice contraception regardless of the gender of the patient during 5 month after last drug exposure~7. Private insurance or government / institution financial support (through CMS or other)~Exclusion Criteria:~1. Pregnancy or breast feeding~2. ALT and/or AST \> 5 x ULN~3. Known, active auto-immune disease;~4. Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing~5. Patients with past history of Solid Organ transplant~6. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load~7. Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours~8. Patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-IL-6R treatments like Tocilizumab or Sarilumab or anti-IL-1 treatment like Anakinra which should preferably be minimized~9. Patients with baseline Rockwood Clinical Frailty Scale ≥ 6 at Hospital admission~10. Patients showing an increase of the NEWS2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration)~11. Patients under guardianship

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYT107 Treatment (Type: EXPERIMENTAL): Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Intramuscular (IM) administration of Saline twice a week for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman between age 18-65 with newly diagnosed Multiple Myeloma for whom stem cell transplantation is considered appropriate~* Measurable serum and/or urinary paraprotein~* European Cooperative Oncology Group performance status 0-3~* Serum bilirubin \< 1.5x the upper limit of normal (ULN) Serum alanine transaminase (ALT)/aspartate transaminase values \< 2.5 x ULN~* Subjects (or their legally acceptable representatives) must signed an informed consent document indicating that they understanding the purpose of and procedures required for the study and are willing to participate in the study~Exclusion Criteria:~* Woman of child bearing potential~* Non-secretory MM~* Serum creatinine \> 400 Micromol/l after initial resuscitation patients with previous Grade 2-4 peripheral neuropathy~* Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)~* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, uncontrolled angina, clinically significant pericardial disease, or III-IV heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- vel 8 - ASCT (Type: EXPERIMENTAL): 8 cycles of velcade with ASCT
- vel4 - ASCT (Type: ACTIVE_COMPARATOR): 4 cycles of velcade with ASCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of a 10 Points Visual Analogue Food Intake Scale for Children to Assess Intake: Prospective Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 6 months to less than 18 years~* Patient admitted in short and long stay pediatric services at the Montpellier University Hospital, other than maternity, neonatality, palliative care or intensive care, excluding SSR.~* Patient admitted for day hospitalization or consultation at the Montpellier University Hospital~Exclusion Criteria:~* Opposition from parents or child~* Pathology involving the satiety centers~* Breast-fed child~* Proven disorder of orality~* Strict fasting by the medical team~* Anorexia nervosa~* Consciousness disorder~* Exclusive artificial feeding

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Laparoscopic or Conventional Mesh Repair of Incisional and Umbilical Hernia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Incisional or umbilical hernia over 2 cm and less than 6 cm in diameter~Exclusion Criteria:~* Patients with a complicated incisional (pain, occlusion, cutaneous necrosis), irreductible painless incisional or umbilical hernia will not be considered as a complication~* Patients with a recurrence of incisional hernia~* Patients with an incisional or umbilical hernia whose lateral edges are located so that fixation of the mesh (which must extend beyond the 4 to 5 cm) is not possible~* Pregnant women~* Patients with HIV therapy~* Patients with cirrhotic ascites or other signs of hepatic insufficiency (bilirubin\> 35 micromol / l; TP \< 55%) or significant thrombocytopenia (\< 60 000 platelets)~* Patients with a contra indication for laparoscopy~* Patients with a life expectancy \< one year, or whose mobility within two years of treatment will damage proper monitoring~* Patients unable to understand information about the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Laparoscopic approach (Type: EXPERIMENTAL): group A: Laparoscopic approach
- Open approach (Type: ACTIVE_COMPARATOR): group B: Open anterior approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Eye Tracking as a Biomarker of Cannabis Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males/non-pregnant females~* Report smoking cannabis ≥1 day per week~* Able to perform all study procedures~Exclusion Criteria:~* Meeting DSM-V criteria for severe substance use~* Use of illicit drugs ≥1 day/week in the prior 4 weeks~* Abnormality with the eyes which may affect the eye tracking technology such as color blindness, naturally occurring nystagmus, amblyopia, strabismus, age-related macular degeneration (AMD), cataract, diabetic eye disease, glaucoma, dry eye, extreme refractive error, bacterial or viral infections of the eye~* 7. User of supplemental oxygen

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active Cannabis (Type: EXPERIMENTAL): In this session, the participant will smoke two-thirds of one active cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
- Placebo Cannabis (Type: PLACEBO_COMPARATOR): In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy